Potential new psoriasis treatment technology reported by Medical College of Wisconsin scientists
Milwaukee, Nov. 28, 2017 – Scientists at the Medical College of Wisconsin (MCW), in collaboration with the Department of Dermatology at the University of California, Davis School of Medicine and several other institutions, recently reported the development of a potential new treatment for psoriasis and other inflammatory diseases. The report, published in the Proceedings of the National Academy of Sciences (PNAS), was the result of a National Institutes of Health-funded study.
The patent-pending technology described in the PNAS paper uses a modified form of the human chemokine CCL20, an immune system molecule involved in the genesis of psoriasis. Treatment with on-market psoriasis medications provide relief, but problems include disease recurrence and decreased immune response. This new prospective therapeutic blocked the movement of T cells into the epidermis, preventing the inflammatory cycle altogether in a mouse model.
"This technology employs a molecule that is so similar to the natural human CCL20 protein that we believe it will have low toxicity and immunogenicity," said Dr. Anthony Getschman, postdoctoral fellow at MCW, a co-inventor of the technology and co-author of the study. "Targeting this pathway could provide better treatment with fewer side effects than on-market drugs."
Dr. Edward Diehl of the MCW Office of Technology Development said, "this technology is an important addition to our intellectual property portfolio and we are seeking a pharmaceutical partner to help bring this to the clinic."
Keep up with the latest news. Sign up for Newsroom Alerts.
Latest press releases, stories and resources.